Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome: Appraisal consultation document

DRAFT guidance does not recommend mogamulizumab for treating mycosis fungoides or Sézary syndrome in adults who have had at least 1 previous systemic treatment, as clinical trial evidence is very uncertain and it was not considered a cost effective use of NHS resources.


National Institute for Health and Care Excellence